Related Experiment Video
Updated: Jul 17, 2025

Isolation of Lung Retinoid-Containing Cells by Cell Sorting
Published on: April 11, 2025
Granulocyte Colony-Stimulating Factor is a Determinant of Severe Bronchopulmonary Dysplasia and Coincident
Lakshanie C Wickramasinghe1, Evelyn Tsantikos1, Alida Kindt2
1Leukocyte Signalling Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Insights
Granulocyte colony-stimulating factor (G-CSF) drives lung and vision damage in premature infants. Targeting G-CSF may offer a new treatment for bronchopulmonary dysplasia and retinopathy of prematurity.
Area of Science:
- Neonatal physiology
- Pulmonology
- Ophthalmology
Background:
- Bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) are common, severe conditions in premature infants.
- Current treatments for BPD are limited to supportive care, and the pathogenesis of both BPD and ROP remains unclear.
Purpose of the Study:
- To investigate the role of granulocyte colony-stimulating factor (G-CSF) in the development of BPD and ROP.
- To explore G-CSF as a potential therapeutic target for these conditions.
Main Methods:
- A neonatal mouse model of hyperoxia-induced BPD and retinopathy was utilized.
- G-CSF levels were measured in hyperoxia-exposed mice and in preterm infants with BPD.
- G-CSF-deficient neonatal pups were assessed for lung injury and ROP development.
Main Results:
- G-CSF was significantly upregulated in response to hyperoxia in mice and elevated in infants with severe BPD.
- G-CSF-deficient pups exhibited reduced lung alveolar simplification, normalized airway resistance, and improved weight gain.
- G-CSF deficiency also mitigated inflammation, oxidative stress, and provided partial protection against ROP.
Conclusions:
- G-CSF acts as a key mediator in the pathogenesis of both BPD and ROP.
- Targeting G-CSF biology presents a promising therapeutic strategy for treating these debilitating neonatal conditions.
Abstract:
Bronchopulmonary dysplasia (BPD), also called chronic lung disease of immaturity, afflicts approximately one third of all extremely premature infants, causing lifelong lung damage. There is no effective treatment other than supportive care. Retinopathy of prematurity (ROP), which impairs vision irreversibly, is common in BPD, suggesting a related pathogenesis. However, specific mechanisms of BPD and ROP are not known. Herein, a neonatal mouse hyperoxic model of coincident BPD and retinopathy was used to screen for candidate mediators, which revealed that granulocyte colony-stimulating factor (G-CSF), also known as colony-stimulating factor 3, was up-regulated significantly in mouse lung lavage fluid and plasma at postnatal day 14 in response to hyperoxia. Preterm infants with more severe BPD had increased plasma G-CSF. G-CSF-deficient neonatal pups showed significantly reduced alveolar simplification, normalized alveolar and airway resistance, and normalized weight gain compared with wild-type pups after hyperoxic lung injury. This was associated with a marked reduction in the intensity, and activation state, of neutrophilic and monocytic inflammation and its attendant oxidative stress response, and protection of lung endothelial cells. G-CSF deficiency also provided partial protection against ROP. The findings in this study implicate G-CSF as a pathogenic mediator of BPD and ROP, and suggest the therapeutic utility of targeting G-CSF biology to treat these conditions.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
COPD: Management Using Bronchodilators and Corticosteroids
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

